| To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia |
|
Haematologica |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Myelodysplastic Syndromes: A Review of Therapeutic Progress Over the Past 10 Years |
|
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
| In Search for a Haemoglobin Threshold in Myelodysplastic Syndromes |
|
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS |
|
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
|
Experimental Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| PNH Phenotypes and Their Genesis |
|
British Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Controversies on the Consequences of Iron Overload and Chelation in MDS |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
